Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients

Ryan Cross

Senior Science Correspondent

Omega Therapeutics, a company designing genetic medicines that dial the output of genes up or down, on Tuesday morning revealed the first data from a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Icon's quarterly earnings hit by biotech and pharma pullback

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients